Imatinib mesylate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Imatinib mesylate
- Molecular weight
- 589.72
- Structure (SMILES)
- CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
- gleevec
- Gleevec
- glivec
- Glivec
- imatinib accord
- Imatinib accord
- imatinib actavis
- Imatinib actavis
- imatinib koanaa
- Imatinib koanaa
- imatinib medac
- Imatinib medac
- imatinib mesylate
- Imatinib mesylate
- imatinib teva
- Imatinib teva
- imatinib teva b v
- Imatinib teva b.v.
- 4 4 methylpiperazin 1 yl methyl n 4 methyl 3 4 pyridin 3 yl pyrimidin 2 yl amino phenyl benzamide methanesulfonate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
- Imatinib (as mesilate)
- imatinib accord
- Imatinib accord
- imatinib accord 400 mg film coated tablets
- imatinib as mesilate
- imatinib medac
- Imatinib medac
- imatinib mesilate
- Imatinib mesilate
- IMATINIB MESILATE [EP MONOGRAPH]
- IMATINIB MESILATE [JAN]
- IMATINIB MESILATE [MART.]
- Imatinib mesilate [WHO-DD]
- imatinib mesilate ep monograph
- imatinib mesilate jan
- imatinib mesilate mart
- imatinib mesilate who dd
- imatinib mesylate
- Imatinib mesylate
- IMATINIB MESYLATE [HSDB]
- IMATINIB MESYLATE [ORANGE BOOK]
- IMATINIB MESYLATE [USAN]
- IMATINIB MESYLATE [VANDF]
And 24 more, listed on the interactive page.
- ATC classification codes
- L01EA01
Sources for recorded values
- CAS registry numbers
- 220127-57-1
- ChEMBL ID
- CHEMBL1642
- InChIKey
- YLMAHDNUQAMNNX-UHFFFAOYSA-N
- PubChem compound IDs
- 123596
- FDA ingredient codes (UNII)
- 8A1O1M485B
- 282388
- 284924
- Applicant
- NOVARTIS
- Approval date
- 18 Apr 2003
- Application number
- NDA021588
- Patents
- 1
- Designations
- 5
- Earliest recorded loss of exclusivity
- 27 Apr 2040
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Drug name stem
- -tinib
Administration routes
- Oral
- Mechanism
- Bcr/Abl fusion protein inhibitor
- Action type
- Inhibitor
- Target
- Bcr/Abl fusion protein
- Protein identifier
- P00519
- Mechanism
- Bcr/Abl fusion protein inhibitor
- Action type
- Inhibitor
- Target
- Bcr/Abl fusion protein
- Protein identifier
- P11274
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
- Action type
- Inhibitor
- Target
- Platelet-derived growth factor receptor beta
- Protein identifier
- P09619
- Mechanism
- Stem cell growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Mast/stem cell growth factor receptor Kit
- Protein identifier
- P10721
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase ABL1
- Protein identifier
- P00519
- Mechanism
- Bcr/Abl fusion protein inhibitor
- Action type
- Inhibitor
- Target
- Bcr/Abl fusion protein
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
- Action type
- Inhibitor
- Target
- Platelet-derived growth factor receptor beta
- Mechanism
- Stem cell growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Mast/stem cell growth factor receptor Kit
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase ABL1
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000094
- Subject identifier
- D054198
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Astrocytoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Chondrosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000333
- Subject identifier
- D002813
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Glioblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neurofibroma, Plexiform
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000658
- Subject identifier
- D018318
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Scleroderma, Systemic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000717
- Subject identifier
- D012595
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Neurilemmoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000760
- Subject identifier
- D009442
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001361
- Subject identifier
- D006976
And 57 more, listed on the interactive page.
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000339
- Condition identifier
- EFO_0000389
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000588
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000658
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000760
- Condition identifier
- EFO_0001361
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001376
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002428
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002429
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004920
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 2
And 119 more, listed on the interactive page.
- Event
- acute lymphocytic leukaemia recurrent
- Reports
- 105
- Reporting signal score
- 295.645
- Event
- blast crisis in myelogenous leukaemia
- Reports
- 119
- Reporting signal score
- 498.483
- Event
- chromosome analysis abnormal
- Reports
- 62
- Reporting signal score
- 257.234
- Event
- chronic myeloid leukaemia
- Reports
- 337
- Reporting signal score
- 1,124.88
- Event
- chronic myeloid leukaemia recurrent
- Reports
- 95
- Reporting signal score
- 409.317
- Event
- cytogenetic analysis abnormal
- Reports
- 202
- Reporting signal score
- 857.328
- Event
- drug intolerance
- Reports
- 574
- Reporting signal score
- 471.748
- Event
- drug resistance
- Reports
- 657
- Reporting signal score
- 1,340.72
- Event
- fluid retention
- Reports
- 255
- Reporting signal score
- 249.254
- Event
- gastric antral vascular ectasia
- Reports
- 70
- Reporting signal score
- 241.138
- Event
- gastrointestinal stromal tumour
- Reports
- 318
- Reporting signal score
- 1,262.9
- Event
- gene mutation identification test positive
- Reports
- 65
- Reporting signal score
- 242.99
- Event
- leukaemia recurrent
- Reports
- 91
- Reporting signal score
- 288.122
- Event
- malignant neoplasm progression
- Reports
- 653
- Reporting signal score
- 860.934
- Event
- metastases to liver
- Reports
- 161
- Reporting signal score
- 237.56
- Event
- muscle spasms
- Reports
- 521
- Reporting signal score
- 304.873
- Event
- neoplasm malignant
- Reports
- 298
- Reporting signal score
- 410.941
- Event
- oedema
- Reports
- 386
- Reporting signal score
- 389.936
- Event
- oedema peripheral
- Reports
- 484
- Reporting signal score
- 246.031
- Event
- pancytopenia
- Reports
- 320
- Reporting signal score
- 235.512
- Event
- periorbital oedema
- Reports
- 216
- Reporting signal score
- 521.967
- Event
- philadelphia chromosome positive
- Reports
- 118
- Reporting signal score
- 488.259
- Event
- pleural effusion
- Reports
- 556
- Reporting signal score
- 667.775
- Event
- second primary malignancy
- Reports
- 510
- Reporting signal score
- 1,514.35
- NCT00002514
- NCT00004932
- NCT00006052
- NCT00006053
- NCT00006343
- NCT00006475
- NCT00015847
- NCT00015860
- NCT00022490
- NCT00028847
- NCT00038610
- NCT00045422
- NCT00053248
- NCT00055874
- NCT00061945
- NCT00064285
- NCT00066326
- NCT00081133
- NCT00093639
- NCT00110058
- NCT00112775
- NCT00244829
- NCT00258271
- NCT00268229
- NCT00301093
And 213 more, listed on the interactive page.
- Dose
- 400-800mg
- Route
- Oral
- How often
- Once daily or twice daily
- A dose of 800 mg should be administered as 400 mg twice a day
- Doses of 400 mg or 600 mg should be administered once daily
- Doses of 800 mg and above should use 400-mg tablets
- Take with a meal and a large glass of water
- Treatment can be given as a once daily dose or split into two doses, morning and evening
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 86.28
- Calculated partition coefficient (ALogP)
- 4.59
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 42
- Molecular formula
- C30H35N7O4S
- Monoisotopic mass
- 589.24712380
- Natural product
- No
- 0078-0401
- 0078-0649
- 0078-1490
- 0093-7629
- 0093-7630
- 0378-2245
- 0378-2246
- 0832-0532
- 0832-0533
- 0904-6621
- 0904-6901
- 31722-296
- 31722-297
- 42292-043
- 42292-044
- 43598-344
- 43598-345
- 47335-472
- 47335-475
- 48433-049
- 48433-050
- 51407-269
- 51407-270
- 59651-240
- 59651-241
And 22 more, listed on the interactive page.
- Recorded assays
- 1,946
- Active assays
- 125
- Confirmatory
- Other
- Screening
- Summary
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
Related records
Trials (245)
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
- A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
- A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
- A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
- A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
- A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.
- A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
- A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
- A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
- A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
- Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
- AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Autologous Transplantation for Chronic Myelogenous Leukemia
- BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Approved for (10)
- Acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia
- Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
- Childhood acute lymphoblastic leukemia
- Chronic myeloid leukemia
- Dermatofibrosarcoma protuberans
- Gastrointestinal stromal tumor
- Hypereosinophilic syndrome
- Lymphoblastic lymphoma
- Myelodysplastic/myeloproliferative disease
In development for (70)
- Acquired polycythemia vera Phase 2
- Acute myeloid leukemia Phase 2
- Adult fibrosarcoma Phase 2
- Asthma Phase 2
- Astrocytoma (excluding glioblastoma) Phase 3
- Breast cancer Phase 2
- Cancer Phase 2
- Carcinoma Phase 2
- Central nervous system neoplasm Phase 2
- Chondrosarcoma Phase 2
- Choroidal neovascularization Phase 1
- Chronic graft versus host disease Phase 2
- COVID-19 Phase 2
- Cutaneous melanoma Phase 2
- Cutaneous neuroendocrine carcinoma Phase 2
- Desmoid tumor Phase 2
- Endometrial cancer Phase 1
- Exocrine pancreatic carcinoma Phase 2
- Fallopian tube cancer Phase 2
- Gastric adenocarcinoma Phase 2